How the tissue around bladder tumors helps drive early bladder cancer to stay or become aggressive
The stromal microenvironment as a co-organizer of bladder carcinogenesis and progression
Researchers are looking at how the cells and signals around early bladder tumors influence whether they stay non‑dangerous or progress to invasive cancer so better tests can be made for people with early bladder cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11192227 on NIH RePORTER |
What this research studies
This Center project studies the tumor microenvironment — the normal and immune cells, structural tissue, and signals surrounding bladder tumors — to understand why some early (non‑muscle‑invasive) bladder cancers recur but never progress while others become invasive. Teams will compare opposing mechanisms that restrain tumors versus those that promote progression using laboratory analyses, molecular profiling, and studies of patient tumor tissue. Findings will be used to develop candidate biomarkers to help sort patients into higher or lower risk groups. The work aims to combine basic biology with clinical samples to create a platform for future risk‑stratified care.
Who could benefit from this research
Good fit: People with non‑muscle‑invasive (early) bladder cancer, especially those with recurrent tumors, would be the most likely candidates to provide samples or benefit from future risk‑stratification tools.
Not a fit: Patients whose cancer is already muscle‑invasive or who have unrelated medical conditions would be unlikely to benefit directly from this early‑stage biomarker research.
Why it matters
Potential benefit: If successful, this work could lead to tests that predict which early bladder cancers are likely to become dangerous and help doctors tailor monitoring and treatment.
How similar studies have performed: Prior research shows the tumor microenvironment influences cancer behavior, but applying a 'tug‑of‑war' model to predict NMIBC progression and developing clinical biomarkers is a novel approach that has not yet been proven.
Where this research is happening
Houston, United States
- Methodist Hospital Research Institute — Houston, United States (Active)
Researchers
- Principal investigator: Chan, Keith Syson — Methodist Hospital Research Institute
- Study coordinator: Chan, Keith Syson
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.